In Brief: Hoffmann-La Roche/Perkin Elmer
This article was originally published in The Gray Sheet
Executive Summary
Hoffmann-La Roche/Perkin Elmer: Enter licensing agreement under which Perkin Elmer's Applied Biosystems Division will develop commercial diagnostic systems that combine Roche's PCR technology with Perkin Elmer's electrophoretic DNA analysis systems. The agreement provides "non-exclusive, limited rights for manufacturing and worldwide distribution of products incorporating PCR for use in fluorescent electrophoresis systems for human in vitro diagnostics," Perkin Elmer says, noting that the agreement allows the technologies to be "used in early diagnosis and potentially more effective treatment for major illnesses" such as cystic fibrosis, colon cancer and breast cancer...